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omatic stem cells cycle slowly or remain quiescent
until required for tissue repair and maintenance.
Upon muscle injury, stem cells that lie between the
muscle ﬁber and basal lamina (satellite cells) are acti-
vated, proliferate, and eventually differentiate to repair
the damaged muscle. Satellite cells in healthy muscle are
quiescent, do not express MyoD family transcription fac-
tors or cell cycle regulatory genes and are insulated from
the surrounding environment. Here, we report that the
S
 
p38
 
 
 
/
 
 
 
 family of mitogen-activated protein kinases (MAPKs)
reversibly regulates the quiescent state of the skeletal mus-
cle satellite cell. Inhibition of p38
 
 
 
/
 
 
 
 MAPKs (a) promotes
exit from the cell cycle, (b) prevents differentiation, and (c)
insulates the cell from most external stimuli allowing the
satellite cell to maintain a quiescent state. Activation of
satellite cells and p38
 
 
 
/
 
 
 
 MAPKs occurs concomitantly,
providing further support that these MAPKs function as a
molecular switch for satellite cell activation.
 
Introduction
 
Maintenance and repair of skeletal muscle tissue is per-
formed by a specialized somatic stem cell termed the satellite
cell. Satellite cells, which comprise a small (1–6%) number
of the total myonuclei, are located between the basal lamina
and the muscle fiber and can remain quiescent for an average
of 7 yr in adult humans (Schultz and McCormick, 1994;
Seale and Rudnicki, 2000; Hawke and Garry, 2001). The
quiescent satellite cell expresses few gene products and does
not express members of the MyoD family (Cornelison and
Wold, 1997; Cornelison et al., 2000). Activation of the satellite
cell, a critical but poorly understood process, can be induced
by HGF or TNF
 
 
 
 injection in vivo (Tatsumi et al., 1998; Li,
2003) and is accompanied by a general initiation of gene
transcription including induction of MyoD and myf-5, an
increase in cellular volume, and entry into the cell cycle
(Cornelison and Wold, 1997; Cornelison et al., 2000). Quiescent
satellite cells express c-met (the HGF receptor), FGF receptors
1 and 4, syndecan-3, and syndecan-4, all of which appear to
be involved in satellite cell activation and proliferation
(Tatsumi et al., 1998; Flanagan-Steet et al., 2000; Cornelison
et al., 2001, 2004).
FGFs and HGF stimulate MAPK signaling cascades,
which have been correlated with the regulation of proliferation
and differentiation in many cell types, including skeletal myo-
blasts. At least four MAPK families have been identified:
the extracellular signal-regulated kinases (ERKs), the c-jun
NH
 
3
 
-terminal kinases/stress activated protein kinase, the p38
MAPKs, and the ERK5 or big MAPKs (Lewis et al., 1998).
The role of MAPK signaling cascades in myogenesis is contro-
versial, as MAPK activation has been implicated in both posi-
tive and negative regulation of myogenic differentiation. These
discrepancies may arise from the different origins of the lines
used and the maintenance of these lines in culture. Depending
on cell type, activation of the MKK1/2–ERK1/2 pathway either
promotes (C3H10T1/2 cells; Gredinger et al., 1998) or inhibits
(23A2, L6A1, and C2C12; Milasincic et al., 1996; Coolican et
al., 1997; Weyman et al., 1997) myogenic differentiation. We
have shown that activation of the Raf–MKK1/2–ERK1/2
module is required for proliferation of the MM14 muscle
satellite cell line, but is dispensable for FGF-dependent inhibition
of terminal differentiation (Jones et al., 2001). Additionally,
activation of the MKK1/2–ERK1/2 pathway is not sufficient to
promote proliferation of MM14 cells, suggesting that addi-
tional FGF-dependent signaling pathways are required. Ectopic
overexpression of MKP-1, a negative regulator of MAPKs, in
C2C12 myoblasts inhibits both proliferation and myoblast
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fusion without affecting expression of muscle-specific genes
(Bennett and Tonks, 1997). Together, these results suggest that
distinct subsets of MAPKs are likely to regulate proliferation
and differentiation of skeletal myoblasts.
The p38
 
 
 
/
 
 
 
 MAPKs, which are activated in response
to growth factor stimulation (Morooka and Nishida, 1998;
Iwasaki et al., 1999; Maher, 1999) have been reported to be
required for late stages of myogenic differentiation of both
C2C12 and L6 myoblasts (Cuenda and Cohen, 1999; Zet-
ser et al., 1999). We found that active p38
 
 
 
/
 
 
 
 (pp38
 
 
 
/
 
 
 
)
MAPKs present in proliferating satellite cells and MM14
cells are localized to the nucleus, suggesting that these ki-
nases may function before cell differentiation. Consistent
with this, we observed that inhibition of p38
 
 
 
/
 
 
 
 MAPK ac-
tivity prevented activation and proliferation of satellite cells
cultured on intact myofibers. We also show that p38
 
 
 
/
 
 
 
MAPKs are required for MyoD induction in satellite cells
and for MM14 differentiation. Interestingly, inhibition of
these MAPKs in either MM14 cells or satellite cells induces
a reversible quiescent state whereby the cells are unrespon-
sive to external stimuli, similar to that observed for normal
adult satellite cells in uninjured muscle tissue.
 
Results
 
Several MAPKs are expressed in proliferating 
and differentiated MM14 cells
 
We have previously shown that ERK1/2 is required for prolif-
eration but not differentiation in MM14 cells (Jones et al.,
2001). To gain insight into which MAPKs may play additional
roles in MM14 cell proliferation and differentiation, we per-
formed RT-PCR for MAPKs on MM14 cells at various times
after induction of differentiation. Neither 
 
erk1
 
, 
 
2
 
 nor 
 
3
 
 MAPKs
appear to change expression levels upon MM14 cell differenti-
ation (Fig. 1 A). Both ERK5 and 
 
p38
 
 
 
 appeared to decrease
during differentiation, whereas 
 
p38
 
 
 
/
 
 
 
 
 
decreased slightly (Fig.
1 A). As a reference, 
 
myoD
 
 shows an increase in mRNA levels
followed by a decrease at 72 h. 
 
fgfr-1
 
, which is lost during dif-
ferentiation, also initially appears to increase and then declines
dramatically by 72 h of differentiation (Fig. 1 A). Although we
expected to observe 
 
erk1/2
 
 in proliferating cells, the presence
of p38
 
 
 
/
 
 
 
 MAPK mRNA in proliferating cells was unex-
pected, as the p38
 
 
 
/
 
  
 
MAPK kinases are reported to be both
sufficient and necessary to promote myogenesis (Cuenda and
Cohen, 1999; Zetser et al., 1999). We asked if the active phos-
Figure 1. p38 /  MAPK is present in proliferating
MM14 cells and is activated by FGF-2. (A) Expression of
MAPKs in proliferating and differentiated MM14 cells.
FGF was removed from MM14 cell cultures at time 0 and
the expression of erk1, erk2, erk3, erk5, p38 / , p38 ,
myoD, and fgfr-1 was determined by RT-PCR. Three
samples for each time point are shown, with increasing
concentrations of input cDNA for each indicated. A loading
control (18S RNA) is also included. (B and C) Proliferat-
ing MM14 cells were fixed and immunofluorescence
performed with anti-pp38 /  antibodies. (C) Digital
deconvolution analysis reveals that pp38 is present in the
cell nuclei as identified by DAPI staining. (D) p38 / 
MAPK is activated by FGF-2 but not 12-O-tetra-deca-
noylphorbol-13-acetate (TPA) in MM14 cells. FGF-medi-
ated phosphorylation of p38 /  MAPK is inhibited by
SB203580 but not by MEK1/2 inhibitors. Cell extracts
were subjected to Western analysis and probed using
anti-pp38 /  antibodies (top) then the blot stripped and
reprobed with anti-p38 /  antibodies (bottom). 
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phorylated p38
 
 
 
/
 
 
 
 (pp38
 
 
 
/
 
 
 
) was present in MM14 cells and
found pp38
 
 
 
/
 
 
 
 localized to the cell nucleus of proliferating
cells (Fig. 1, B and C). Because MM14 cells are exquisitely
sensitive to FGF removal, which is sufficient to trigger differ-
entiation from the G1 phase of the cell cycle, we asked if re-
moval of FGF would promote p38
 
 
 
/
 
 
 
 activation. Upon re-
moval of FGF in the presence of 15% horse serum, we found
little if any detectable pp38
 
 
 
/
 
 
 
 MAPK (Fig. 1 D, top). How-
ever, FGF-2 addition to starved MM14 cells robustly stimu-
lated p38
 
 
 
/
 
 
 
 phosphorylation (Fig. 1 D). The activation of
these MAPKs appears specific because it was blocked by incu-
bation with the p38 inhibitor SB203580 but was insensitive to
ERK1/2 inhibitors (Fig. 1 D). The apparent activation of p38
 
 
 
/
 
 
 
MAPKs by FGF-2 is not due to changes in p38
 
 
 
/
 
 
 
 protein lev-
els as indicated by reprobing the Western blot with an antibody
that recognizes p38
 
 
 
/
 
 
 
 (Fig. 1 D, bottom).
 
Active p38
 
 
 
/
 
 
 
 is required for 
proliferation of MM14 cells
 
FGF-mediated activation of p38
 
 
 
/
 
 
 
 MAPKs and their presence
in the nucleus of proliferating myoblasts were unexpected, sug-
gesting a role for these MAPKs in proliferating myoblasts. We
asked what effect inhibition of p38
 
 
 
/
 
 
 
 MAPKs would have on
proliferating MM14 cells. If synchronized by mitotic shake-off
MM14 cells require FGF within 4-6 h to proceed through the
cell cycle (Clegg et al., 1987; Kudla et al., 1995) and thus we
tested the effect of increasing doses of SB203580 on synchro-
nized MM14 cells. Addition of SB203580 to proliferating cells
prevented DNA synthesis in a dose-dependent manner, reduc-
ing DNA synthesis to control levels with 25 
 
 
 
M SB203580
(Fig. 2 A). To demonstrate that the SB203580-dependent inhi-
bition of proliferation is specific for the p38
 
 
 
/
 
 
 
 MAPKs, we
attempted to rescue the SB203580 effects with an SB203580-
resistant p38
 
 
 
 (p38
 
 
 
TM
 
; Eyers et al., 1999). In the presence
of SB203580, MM14 cells expressing a control vector or
wild-type p38
 
 
 
 failed to proliferate (Fig. 2 B). In contrast,
SB203580-treated cells expressing p38
 
 
 
TM
 
 proliferated, dem-
onstrating rescue by the drug-resistant p38
 
 
 
TM
 
 (Fig. 2 C). To-
gether, these data support the conclusion that p38
 
 
 
/
 
 
 
 MAPKs
are required for myoblast proliferation and that the phenotype
of SB203580-treated cells is specifically due to loss of p38
 
 
 
/
 
 
 
MAPK activity.
 
Active p38
 
 
 
/
 
 
 
 is present in recently 
activated satellite cells
A role for p38 /  MAPKs has not been demonstrated in pro-
liferating myoblasts and thus might potentially reflect an arti-
fact of the MM14 cell line. Therefore, we asked if p38 / 
MAPKs were present in activated satellite cells cultured on in-
tact myofibers. The p38 /  MAPKs appear present in freshly
isolated myofibers at the time of muscle harvest. The protein
appears localized in the cytoplasm of the myofibers adjacent
to the myonuclei (Fig. 3 A, asterisk in myofiber panel). In ad-
dition, immunoreactive p38 /  was present in quiescent skel-
etal muscle satellite cells (Fig. 3 A, caret), readily identified
by their syndecan-4 staining (Cornelison et al., 2001). In the
satellite cells, the p38 /  MAPKs appear to localize to the cy-
toplasm (Fig. 3 A). If p38 /  MAPKs are required for satellite
cell proliferation, pp38 /  should be present. When stained
with an antibody that recognizes pp38 /  satellite cell nuclei
on myofibers fixed at the time of harvest and on myofibers af-
ter 3 and 24 h of culture were pp38 /  positive (Fig. 3 B).
When muscle tissue was removed, fixed, and myofibers teased
from the fixed muscle tissue, 40% of the satellite cells were
immunoreactive for pp38 /  (Fig. 3, B and C). This number
increases rapidly to  80% by 24 h in culture (Fig. 3 C) before
cell division at 36 h. The appearance of pp38 /  in muscle
tissue immediately upon harvest suggests that p38 /  phos-
phorylation may rapidly occur upon satellite cell activation.
Although we removed muscle tissue and fixed the tissue
immediately, a minimum of 15–20 min required to dissect the
muscle is essentially a massive injury and likely results in sat-
ellite cell activation. Thus, we expect isolation of muscle tis-
sue to activate satellite cells. However, the induction of MyoD
expression, regarded as an early marker for satellite cell acti-
vation was not detected until after 3 h of myofiber culture
(Fig. 3 B). The frequency of pp38 /  immunoreactivity in sat-
ellite cells is significantly higher than that of MyoD at 0.4 and
3 h of myofiber culture (Fig. 3 C), revealing that p38 / 
MAPKs are activated before MyoD accumulation in satellite
cells (Fig. 3, B and C) and that both events occur before satel-
lite cell duplication.
Figure 2. p38 /  MAPK activity is required for MM14 cell proliferation.
(A) MM14 cells synchronized by mitotic shake-off were grown in the
presence or absence of added FGF-2 and treated with either DMSO (control)
or increasing concentrations of SB203580, and DNA synthesis deter-
mined by [
3H]thymidine incorporation. (B) MM14 cell were cotransfected
with expression vectors encoding  -galactosidase, p38 , or p38 TM and
pcDNA as indicated to rescue SB203580 inhibition of p38 /  activity.
Cells were incubated in either DMSO carrier (white bars) 20  M (gray
bars) or 40  M SB203580 (black bars) for 36 h then fixed, stained for
 -galactosidase to identify transfected cells and scored. The data represent
two independent experiments performed in quadruplicate.JCB • VOLUME 169 • NUMBER 1 • 2005 108
Active p38 /  MAPKs are required for 
satellite cell activation and proliferation
Our data suggests that pp38 /  may play a role in the activated
satellite cell. To elucidate the function(s) of p38 / , we first
tested for toxicity and verified that the p38 /  MAPK inhibitors
would function on satellite cells in myofiber cultures. Addition
of SB203580 (Davies et al., 2000) but not an inactive analogue,
SB202474, at the time of myofiber isolation eliminated satellite
cell immunoreactivity for pp38 /  MAPKs (Fig. 4 A), which
were readily detectable by syndecan-4 staining (Fig. 4 A).
We assayed for induction of MyoD protein in fiber-asso-
ciated satellite cells as a measure of satellite cell activation in
the presence and absence of pp38 /  MAPK inhibitors. Addi-
tion of an inactive analogue, SB202474, had no detectable ef-
fect on MyoD protein induction in syndecan-4–positive satel-
lite cells (see Fig. 6 A). Culturing intact myofibers in either
active analogue (SB203580 or SB202190) did not detectably
affect the satellite cell number at 24 h after isolation (Fig. 3 D,
not depicted) but significantly diminished MyoD induction
(Fig. 4 B). Quantitative analysis of these data show that treat-
ment with either active analogue reduces the number of satel-
lite cells that detectably express MyoD protein by 50% and
60% for SB202190 and SB203580, respectively, when com-
pared with the SB202474 control (Fig. 4 C).
Proliferation of satellite cells on intact myofibers was also
blocked by addition of SB203580. Intact myofibers treated for
48 h with SB203580 (Fig. 4 D) or 96 h (not depicted) possessed
satellite cells as shown by syndecan-4 staining but these cells
failed to incorporate BrdU (Fig. 4 D). When untreated myofi-
bers are scored for the number of satellite cells per myofiber at
96 h in culture, a broad distribution is observed with an average
of 12–14 satellite cells per fiber (Fig. 4 E). In contrast, fibers in-
cubated for 96 h in SB203580 had a narrow distribution of satel-
lite cells with an average of three to four satellite cells per fiber
(Fig. 4 E), similar to the average number of satellite cells at
the time of myofiber isolation, suggesting a role for p38 / 
MAPKs in satellite cell activation and subsequent proliferation.
Active p38 /  MAPKs are necessary for 
MM14 and satellite cell differentiation
Published data has clearly demonstrated a requirement for
p38 /  in myogenic differentiation, where p38 /  is reported
to regulate MEF-2 activity and transcriptional activity of MyoD
and myogenin (Zetser et al., 1999; Puri et al., 2000; Wu et
al., 2000). A similar requirement for p38 /  activity in MM14
cell differentiation was revealed by treating MM14 cells with
SB203580. MM14 cells grown in proliferation media are  5%
MyHC positive after 36 h (Fig. 5 A) and 15% MyHC positive
after 72 h (not depicted). In the presence of SB203580, there
were no detectable MyHC-positive cells at 36 h (Fig. 5, A and
B). When incubated for 36 h in differentiation media, 98% of
the cells were MyHC-positive in the absence of the drug (Fig. 5,
A and B) and only 20% were positive when SB203580 was in-
cluded (Fig. 5, A and B). These data agree with those previously
published and suggest that the p38 /  MAPKs are required for
differentiation of the MM14 satellite cell-derived cell line.
Proliferation and differentiation are mutually exclusive
events in skeletal muscle cells and thus, it is difficult to reconcile
Figure 3. p38 /  MAPK is phosphorylated immediately upon myofiber removal. (A) Intact myofibers isolated from fixed adult mouse hindlimb muscle tis-
sue as quickly as possible (time 0.4) or live myofibers isolated and cultured for the indicated times (3 h, 24 h) were fixed and stained for syndecan-4
(green) to identify satellite cells. The fibers were also stained with primary antibodies for p38 /  (A, red), pp38 /  (B, top, red), or MyoD (B, bottom,
red). Asterisks mark p38 /  immunoreactivity and carets identify syndecan-4–positive satellite cells. All cultures were mounted in DAPI (blue) to identify
nuclei. (C) Data obtained from myofiber cultures were quantified, and the number of pp38 /  MAPK-positive (white bars) or MyoD-positive (black bars)
cells were graphed relative to the total number of syndecan-4–positive satellite cells. The data obtained were combined from three independent experi-
ments. Error bars represent the SEM.P38 /  MAPKS ACTIVATE SATELLITE CELLS • JONES ET AL. 109
a requirement for p38 /  MAPKs in both events. It is possible
that the p38 /  inhibitors are nonspecifically blocking myogen-
esis. Therefore, we tested the capacity of the p38 TM (Eyers et
al., 1999) to rescue differentiation in SB203580-treated MM14
cells. MM14 cells maintained in the absence of FGF and in
DMSO for 48 h express MyHC, but cells maintained in
SB203580 fail to differentiate (Fig. 5 C). However, MM14 cells
expressing p38 TM induce MyHC expression even when main-
tained in SB203580 for 48 h (Fig. 5 C). Moreover, SB203580-
treated MM14 cells expressing p38 TM induce skeletal muscle-
specific gene expression whereas treated cells expressing p38 
fail to induce muscle gene expression when assayed by a mus-
cle-specific reporter assay (Fig. 5 D). Together, these data estab-
lish that inhibition of differentiation by SB203580 in MM14
cells is specific for p38 /  MAPKs and not due to nonspecific
activities even at high (20  M) SB203580 concentrations.
Differentiation of primary satellite cells dispersed in
monolayer culture is also inhibited when cultured in 20  M
SB203580 for 48 h (Fig. 5 E). The inhibitory effects of
SB203580 on satellite cell differentiation appears similar to
that seen for MM14 cells.
The requirement for p38 /  in 
proliferation and differentiation 
occurs in the G1 phase of the cell cycle
A requirement for p38 /  activity in proliferation and differen-
tiation of skeletal muscle MM14 cells appears counterintuitive
because these events are mutually exclusive. These results
could be explained if p38 /  functioned in the G1 phase of
proliferating cells to promote progression through the cell cy-
cle and in the G0 phase to promote differentiation, perhaps by
acting on distinct targets. To determine when in the cell cycle
p38 /  functions are required, we synchronized cells by mi-
totic shake-off at the M/G1 boundary and added SB203580 at
different times in the presence and absence of FGF-2 (Fig. 6
A). In untreated cultures, cells irreversibly withdraw from the
cell cycle if FGF-2 is removed for 4–6 h after cell synchroniza-
tion (see Fig. 7 A), indicated by loss of [
3H]thymidine incor-
poration (Fig. 6 B). If synchronized cells are treated with
SB203580 at 2, 4, or 6 h after mitotic shake-off, the cells fail to
enter the cell cycle and do not incorporate [
3H]thymidine (Fig.
6 B). However, if SB203580 is added after 6 h there is little ef-
fect on DNA synthesis, suggesting the requirement for p38 / 
Figure 4. p38 /  MAPK is required for satellite cell proliferation. (A) Intact myofibers were incubated upon removal with either an inactive p38 / 
MAPK inhibitor, SB202474, or SB203580 for 24 h. pp38 /  was identified by staining with anti-pp38 /  antibodies and satellite cells identified by
staining with syndecan-4. Nuclei were identified by staining with DAPI. (B) Mouse hindlimbs were removed and muscle fibers dissected and cultured in
either SB202474, SB203580, or SB202190 for 24 h. The myofibers were then fixed and stained for syndecan-4 (green), MyoD (red), and DAPI (blue).
(C) The number of MyoD-positive cells and syndecan-4–positive cells treated with each agent were scored and the number of MyoD-positive cells plotted
as a percentage of the total number of satellite cells. (D) Satellite cells on intact myofibers were incubated in BrdU-containing medium in DMSO (top) or
SB203580 for 48 h (bottom). The myofibers were probed with anti–syndecan-4 antibodies and anti-BrdU antibodies to identify satellite cells and DNA
synthesis, respectively. (E) Intact myofibers were cultured as in D for 96 h. The fibers were fixed and stained with anti–syndecan-4 antibodies to identify
satellite cells. The frequency of the number of satellite cells scored was plotted as a function of the average number of satellite cells per myofiber. Carets
denote syndecan-4–positive satellite cells in all panels.JCB • VOLUME 169 • NUMBER 1 • 2005 110
in proliferation occurs in the G1 phase (Fig. 6 B). To determine
the point in the cell cycle when differention of MM14 cells are
sensitive to SB203580, cells were synchronized, plated in the
absence of FGF-2 and SB203580 was added at 6-h intervals up
to 24 h. The cells were maintained for an additional 36 h in cul-
ture and were fixed and stained to quantify the percentage of
MyHC-positive cells. Addition of SB203580 prevented MyHC
induction only if added within the first 6 h after mitotic shake-
off (Fig. 6 C). Thus, the temporal requirement for p38 /  ac-
tivity appears to be similar to promote both proliferation and
differentiation. Interestingly, when MM14 cells are treated
with SB203580 both proliferation and differentiation are
blocked, inducing an unresponsive state in which the cells ap-
pear quiescent and viable.
P38 /  MAPKs signal to different 
substrates in proliferating or 
differentiated MM14 cells
A requirement for p38 /  in both proliferation and differenti-
ation could be explained if p38 /  MAPKs acted on different
substrates in proliferating cells versus cells committed to ter-
minal differentiation. To ask if these MAPKs signal differen-
tially we analyzed p38 /  activity using the CHOP reporter
assay specific for the ATF2 transcription factor (Xu and
Cobb, 1997). Surprisingly, proliferating MM14 cells display
CHOP reporter activity but this activity appears insensitive to
FGF and insensitive to SB203580 (Fig. 7 A). At this time
point the majority of cells are not committed to differentiation
in the presence or absence of FGF-2. In contrast, if cells are
cultured for 72 h in the absence of FGF-2, a large induction of
CHOP is observed (Fig. 7 A). As expected, this activity is
sensitive to SB203580, indicating that it is dependent on the
p38 MAPKs. In proliferating cells, pp38 /  signals indepen-
dently of ATF2 whereas in differentiated cells pp38 /  acti-
vates ATF2-dependent transcription denoting distinct differ-
ences in p38 MAPK signaling that appear dependent on the
cellular phenotype.
An independent and less biased approach for identifying
p38 /  MAPK substrates in proliferating and differentiated
cells was performed by immunoprecipitation of cell extracts
Figure 5. p38 /  MAPK activity is required for terminal
differentiation of MM14 and satellite cells. (A) MM14
cells grown for 36 h (A) in the presence or absence of
FGF-2 and in DMSO (control, top) or 25  M SB203580
(bottom) were fixed and stained for MyHC. (B) MyHC-
positive cells were scored as a percentage of entire popu-
lation in proliferation (black bar) or differentiation (white
bars) media with a minimum of 3,000 total cells scored
for each data point. Error bars represent the SD of three
independent samples from one experiment. (C) Carets
mark MyHC-positive cells. MM14 cells expressing  -gal
(top) or  -gal and p38 TM (bottom) were grown for 36 h
in the absence of FGF-2 and in DMSO or 20  M
SB203580 as indicated, fixed, and stained for  -galac-
tosidase (green) and for MyHC (red). In DMSO-treated
cells transfected and untransfected cells express MyHC
whereas only p38 TM-transfected cells are MyHC-positive
in the presence of SB203580. (D) MM14 cells cotrans-
fected with LacZ, an  -cardiac actin promoter driving
luciferase (the MSP reporter), and either pcDNA3, p38 ,
or p38 TM expression vectors were grown for 48 h with
or without (20  M) SB203580 in the presence or absence
of FGF-2 and processed for luciferase assays. The extent
of differentiation (RLU) in the presence and absence of
FGF without SB203580 for each transfection was normal-
ized to 1.0-fold to compare with transfected cells treated
with SB203580. In p38 TM-expressing cells but not in
control or p38-transfected cells differentiation was rescued
despite the presence of SB203580. (E) Dispersed primary
satellite cell cultures were cultured for 48 h in differentiation
conditions in the presence or absence of 20  M
SB203580. The cells were fixed, stained for syndecan-4
and MyHC and the number of MyHC-positive satellite
cells scored. The number of MyHC-positive satellite cells was
normalized to 100% in DMSO-treated cultures. All error
bars indicate SEM for four independent experiments.P38 /  MAPKS ACTIVATE SATELLITE CELLS • JONES ET AL. 111
with an antibody that recognizes MAPK phosphorylation sites.
Immunoprecipitation of MM14 cell extracts maintained in the
presence of FGF-2 for 24 h (proliferating) or in the absence of
FGF-2 for 48 h (differentiated) in the presence and absence of
SB203580 reveal a number of potential p38 /  MAPK sub-
strates unique to proliferating cells (Fig. 7 B, black arrow-
heads) and differentiated cells (Fig. 7 B, white arrowhead).
These data provide further evidence that p38 /  MAPK func-
tions differently in proliferating and differentiated cells. The
majority of the bands present in the gel do not change when
cells are treated with SB03580, indicating they are likely sub-
strates of other MAPKs. The majority of proteins that change
in intensity or mobility upon treatment with SB203580 are dis-
tinct for either the proliferating or differentiated cell popula-
tions. These data indicate that the majority of p38 /  sub-
strates detected by this method are unique for each cellular
phenotype (Fig. 7 B). Although we have not yet identified and
verified these potential substrates, these data suggest that the
functions performed by pp38 /  in proliferating and differenti-
ated cells substantially differ.
Loss of p38 /  activity defines a 
reversible quiescent state for MM14 
cells and satellite cells
We observed that MM14 cells treated with SB203580 exited
the cell cycle but also failed to differentiate. This “quiescent
state” closely resembles a similar quiescent state that occurs in
the majority of the normal adult satellite cell population in
vivo. Because the SB203580-treated cells exhibit characteris-
tics similar to quiescent satellite cells we predicted that (a) cells
will be unresponsive to changes in culture conditions while
maintained in SB203580, and (b) that the SB203580-induced
quiescence will be reversible. To test this hypothesis, MM14
cells were treated either with DMSO as a control or with
SB203580 for 36 h in differentiation media (D   5% horse se-
Figure 6. Active p38 /  MAPK is required in the G1-phase for commitment
to either S-phase or to terminal differentiation. (A) Experimental schematic
illustrating that withdrawal of FGF from synchronized MM14 cells for 4–6 h
induces an irreversible commitment to terminal differentiation. (B) MM14
cells were synchronized at the M/G1 boundary and at the indicated times
received 500 pM FGF-2(—) or FGF-2 and 25  M SB203580(   ). Cells
were grown 14 h in the presence of 
3[H]thymidine and the cpm incor-
porated into the DNA quantified and plotted as a function of the time in
culture after mitotic synchronization. (C) Cells were synchronized, cultured
in the absence of FGF-2 with SB203580 added at the indicated times and
cultures incubated for an additional 36 h. The cells were fixed, stained for
MyHC and the percentage of MyHC-positive cells plotted as a function of
the time of addition of the drug. Error bars represent the SD of three inde-
pendent experiments.
Figure 7. p38 /  functions differently in proliferating versus differentiated
MM14 cells. (A) MM14 cells cotransfected with the pFA-CHOP/pFR-Luc re-
porter system and CMV-LacZ. pFR-Luc expressed alone is not detectable
(not depicted). Cells were cultured with the indicated treatments for 24 or
72 h in the presence (white bars) or absence (black bars) of FGF-2. The
CHOP assay activity in proliferating cells at 24 h after transfection is not
affected by either FGF-2 or SB203580. In contrast, CHOP activity 72 h af-
ter transfection is sensitive to FGF-2 and SB203580, suggesting p38 / 
signals via ATF2 in differentiated but not proliferating cells. Error bars rep-
resent the SD of three independent experiments. (B) Cell extracts from
proliferating (P) or differentiated (D) MM14 cells maintained in 20  M
SB203580( ) or DMSO( ) for 24 and 48 h, respectively, were immuno-
precipitated with an antibody directed to phospho-T/S-P (Novus), proteins
separated by SDS-PAGE and detected by silver staining. MW standards
are indicated on the left. Closed arrows indicate proteins appearing in
proliferating cells that are SB203580 sensitive and absent in differenti-
ated cells (large and small arrows indicate prominent and minor bands,
respectively). The open arrow indicates an SB203580-sensitive protein
that is present only in differentiated cells. The immunoprecipitation was re-
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rum and no FGF-2). The drug was removed and the treated
cells incubated an additional 24 h in proliferation media (P  
15% horse serum and 500 pM FGF-2) or in D media with
3[H]thymidine. Incorporation of 
3[H]thymidine into the DNA
in control cultures maintained in DMSO under proliferating
conditions was normalized to 100% (Fig. 8 A). Incorporation
of 
3[H]thymidine into DNA in cultures maintained in D condi-
tions for 36 h was  5% of the proliferating control (Fig. 8 A)
yet cells maintained for 36 h in D conditions with added
SB203580 reentered the cell cycle upon removal of the inhibi-
tor and restoration of P media (Fig. 8 A). These data indicate
that SB203580-treated cells are indifferent to their environ-
ment because they show no effects of either P or D media dur-
ing SB203580 treatment but proliferate or differentiate solely
based on the conditions they are exposed to after SB203580 is
removed. This effect is drug specific as cells cultured in its ab-
sence for 36 h in D conditions fail to reenter the cell cycle
when switched to P media (Fig. 8 A).
When MM14 cells are maintained for 36 h in DMSO and
D conditions, MyHC is induced in  95% of the cells (Fig. 8 B),
whereas  5% of the cells are MyHC positive if maintained in P
conditions for 36 h (Fig. 8 B). Because MM14 cells can undergo
terminal differentiation from G1 without an intervening cell cy-
cle when FGF is removed, we asked if cells maintained in
SB203580 were similarly capable of committing to terminal dif-
ferentiation without an intervening S-phase. When cells treated
with SB203580 for 36 h in D conditions were cultured for an
additional 24 h in the absence of the drug, the majority of the
cells differentiated (Fig. 8 B). In contrast, cells maintained in
SB203580 and D conditions for 36 h and then switched to P
conditions were  5% positive for MyHC (Fig. 8 B). These re-
sults are consistent with the idea that inhibition of p38 / 
MAPKs maintains MM14 cells in a quiescent, nonresponsive
state, and the cells are incapable of responding to either the pres-
ence or absence of FGF-2. Upon SB203580 removal, MM14
cells can either commit to S-phase or to terminal differentiation,
depending on the environmental signals provided.
To test whether p38 /  MAPK activation was required
for exit from a quiescent state in satellite cells and to test if in-
hibition of these MAPKs maintained satellite cell quiescence,
we performed a series of experiments on satellite cells similar
to those described for MM14 cells. Satellite cells on intact myo-
fibers were maintained for various times in the presence of
SB203580 and BrdU to assess satellite cell proliferation. Intact
myofibers cultured under normal conditions will induce DNA
synthesis  36 h after myofiber isolation (Fig. 8 C). If the fibers
are cultured in the presence of SB203580, satellite cells fail to
incorporate BrdU by 48 h reflecting a failure to activate and
proliferate (Fig. 8 C). This is not due to loss of satellite cells
because inclusion of SB203580 does not appear to decrease the
number of satellite cells below that seen at initial harvest (Figs.
5 and 7). Removal of the p38 inhibitor at 24 h of culture rapidly
reverses satellite cell quiescence, promoting DNA synthesis in
50 and 100% of the population within 24 and 48 h, respectively
(Fig. 8 C).
Discussion
Skeletal muscle satellite cells are among the best understood
adult somatic stem cell types and possess a tremendous capac-
ity for regeneration of skeletal muscle tissue (Schultz and Mc-
Cormick, 1994; Hawke and Garry, 2001; Seale et al., 2001).
Skeletal muscle satellite cells are mitotically quiescent in adult
Figure 8. SB203580 dependent inhibition of proliferation and differentiation
are reversible in MM14 and satellite cells. (A–C) MM14 and satellite cells
were incubated initially in the presence or absence of 25  M SB203580
(SB) for the times as indicated in either P (white bars) or D (black bars)
media. (A) MM14 cultures were washed after 36 h in culture, removing
the drug, if present. Cultures were incubated for an additional 24 h in the
indicated conditions with 
3[H]thymidine included in the culture medium.
The cells were harvested, the 
3[H]cpm counted and plotted as a function of
the cell treatment paradigm. (B) MM14 cells were treated as described
above for A except that 
3[H]thymidine was not added and cells were fixed
and stained for MyHC. The percent MyHC-positive cells were plotted as a
function of the treatment paradigm. (C) Intact myofibers were cultured in
BrdU and with or without SB203580 for the times indicated, washed to
remove the drug if present and incubated in fresh media for the additional
times indicated. The fibers were harvested and stained for syndecan-4 to
identify satellite cells and for BrdU incorporation to identify cells actively
synthesizing DNA. The number of BrdU-positive satellite cells was plotted
as a function of the treatment paradigm. Error bars represent the SEM
from at least three independent experiments.P38 /  MAPKS ACTIVATE SATELLITE CELLS • JONES ET AL. 113
uninjured skeletal muscle tissue and may remain quiescent for
years in humans (Schultz et al., 1978; Schultz and McCormick,
1994). As such, satellite cells maintain a low metabolic profile
and maintain gene expression for a small subset of growth-
related genes that include FGF receptors 1 and 4 and c-met but
no detectable expression of cell cycle–related genes or myo-
genic transcription factors (Cornelison et al., 2000). Satellite
cell activation occurs rapidly after muscle injury; once acti-
vated, satellite cells induce expression of the myogenic regula-
tory factors, commit to DNA synthesis and begin proliferating
in vivo (Schultz and Jaryszak, 1985; Schultz, 1996) and on in-
tact myofibers (Bischoff, 1986; Yablonka-Reuveni and Rivera,
1994; Cornelison and Wold, 1997). Removal of myofibers
from intact skeletal muscle simulates an injury response, acti-
vating satellite cells with an accompanying rapid increase in
cytoplasmic volume. Robust gene expression begins with
the initiation of myogenic regulatory factor expression where
MyoD is observed in 20–40% of the cells 3–6 h after isolation
and 50–70% of the cells at 24 h. Proliferation is nearly syn-
chronous for the first two divisions, occurring every 30–36 h
(Bischoff, 1986; Cornelison and Wold, 1997).
Satellite cells within the muscle are both rare, comprising
only 1–6% of the total muscle nuclei, and isolated; thus, little is
known regarding the intracellular pathways regulating their ac-
tivation, proliferation, and differentiation. We have been inves-
tigating the role(s) of MAPKs in skeletal muscle satellite cells
in the MM14 satellite cell line, explanted myofibers and in dis-
persed cultures of satellite cells (Jones et al., 2001). For the p38
MAPK family, work performed on either myogenic cell lines
or in fibroblasts (10T1/2) cells converted to muscle by ectopic
MyoD expression shows that p38 /  MAPKs promote myo-
genesis, presumably via mechanisms that influence the tran-
scriptional activation of the MyoD and MEF2 families (Cuenda
and Cohen, 1999; Zetser et al., 1999; Puri et al., 2000; Wu et
al., 2000; Xu et al., 2002). However, when examining the role
of p38 /  MAPKs in the context of a developing limb it was
observed that myogenesis was significantly enhanced when
p38 /  MAPKs were inhibited, the opposite of what would be
predicted for the role of p38 /  from studies involving myo-
genic cell lines (Weston et al., 2003). Explanations for these
disparate observations have not yet been forthcoming.
The consequences of p38 /  inhibition are manifested as
a failure to differentiate (a phenotype that is observed when
p38 /  is inhibited in the MM14, C2C12, and L6/L8 cell lines)
and a failure to proliferate in both MM14 cells and satellite
cells, a novel observation. The inhibition of proliferation and the
block to differentiation both occur when p38 /  activity is in-
hibited in the G1 phase of the cell cycle. Targets of the p38 / 
MAPKs that mediate these events are unidentified. Although a
significant body of data has shown that MEF2A and MEF2C are
substrates of p38  and p38 2 (Ornatsky et al., 1999; Yang et
al., 1999), satellite cells do not express detectable MEF2 tran-
scripts until 96 h after myofiber isolation, suggesting that these
are unlikely p38 /  targets for satellite cell activation or prolif-
eration. Other known substrates of p38 /  include transcription
factors (Max and ATF2), kinases (MAPKAP kinase 2 and 3),
and phospholipase A2 (Lewis et al., 1998). In proliferating
MM14 cells, manipulation of p38 /  activity by FGF removal
or by SB203580 addition has no significant effect on ATF2-
dependent transcription. However, in differentiated cells, ATF2-
dependent transcription is SB203580 and FGF-2 sensitive. This
suggests that p38 /  MAPKs act upon different substrates in
proliferating and differentiating cells. A similar observation
was noted for MM14 cells where differential activation of
the ERK1/2 pathway occurred in cells committed to S-phase
as compared with cells committed to terminal differentiation
(Campbell et al., 1995). These reports provide supporting evi-
dence for differences in signaling pathways that are dependent
on the phenotypic state of skeletal muscle cells. When further
analyzed for differences in substrate specificity, we found that
the majority of p38 /  substrates were different in proliferating
versus differentiated cells. Thus, the observation that p38 / 
MAPKs are required for both proliferation and differentiation
could be explained by differential substrate accessibility im-
posed by commitment of the cell to S-phase or to terminal dif-
ferentiation. A better understanding of the roles of p38 / 
MAPKs in these events will require identification of substrates
specific for cells committed to proliferate and differentiate.
A requirement for p38 /  MAPKs in satellite cell prolif-
eration appears similar to that observed in MM14 cells. How-
ever, pp38 /  is detected in the cell nucleus of satellite cells
within 20 min of isolation, suggesting that these MAPKs may
play a role in signaling pathways that participate in activation
of satellite cells. Consistent with this suggestion is the observa-
tion that inhibition of p38 /  activity in satellite cells prevents
MyoD induction and proliferation, both markers of satellite cell
activation. Although these data support a role for p38 / 
MAPKs in satellite cell activation, the role of these kinases ap-
pears more complicated. Our data suggest that p38 /  is criti-
cal for balancing satellite cell activation and quiescence. Sup-
porting this hypothesis is the observation that both cultured
satellite cells and MM14 cells fail to respond to changes in se-
rum concentrations or FGF-2 when p38 /  is inhibited, indi-
cating a general unresponsiveness to environmental stimuli.
Importantly this unresponsive or quiescent state is reversible in
Figure 9. A model for the function of p38 /  MAPK in satellite cell
activation. Upon injury to the muscle tissue, the p38 /  MAPK is immediately
activated by as yet unidentified signals that may include signaling from either
FGF receptor-1, FGF receptor-4, c-met, or the TNF -receptor. Once activated,
p38 /  MAPK activity is maintained to allow satellite cell proliferation
and reparation of damaged tissue. Activated p38 /  is also required for
cell differentiation, and acts on distinct substrates to promote proliferation
and differentiation. The quiescent state is maintained by inhibition of
p38 /  MAPKs presumably via MAPK phosphatases.JCB • VOLUME 169 • NUMBER 1 • 2005 114
both MM14 and satellite cells. When SB203580 is removed,
MM14 cells can either reenter the cell cycle and proliferate or
exit the cell cycle and terminally differentiate upon addition of
P or D media, respectively. Satellite cells on intact myofibers,
which do not undergo differentiation reenter the cell cycle
upon SB203580 removal. Because the behavior of MM14 and
satellite cells in SB203580 resembles the quiescent state of sat-
ellite cells in adult uninjured skeletal muscle tissue, we propose
that activation of p38 /  functions as an intracellular “molecu-
lar switch” for satellite cell activation (Fig. 9).
In vivo, mechanical stress activates satellite cells via an
HGF and NO-dependent mechanism (Tatsumi et al., 2002); ac-
tivation also occurs upon in vivo administration of TNF  (Li,
2003). It is noteworthy that p38 /  MAPKs are also activated
by mechanical stress (Cowan and Storey, 2003; Kumar et al.,
2003; Wretman et al., 2001), HGF (Recio and Merlino, 2002),
TNF  (Geng et al., 1996; Roulston et al., 1998) and FGFs. Cel-
lular stress responses often lead to an inflammatory response
involving activation of p38 /  MAPKs in immune-responsive
cells (Cowan and Storey, 2003; Kumar et al., 2003) and in skel-
etal muscle tissue (Wretman et al., 2001), where a severe
stretch is capable of p38 activation. Our model (Fig. 9) for reg-
ulation of satellite cell activation proposes that these physio-
logical events activating satellite cells is mediated via activa-
tion of p38 /  MAPKs. We further predict that the satellite
cell quiescent state is maintained by inhibition of p38 / 
MAPKs, presumably via a p38 /  MAPK phosphatase, per-
haps MKP-1 (Bennett and Tonks, 1997).
We propose that activation of the skeletal muscle satellite
cell, a well-studied adult somatic stem cell, is concomitant with
the activation of p38 /  MAPKs and suggest that these MAPKs
function as a molecular switch determining the activation state
of the satellite cell. The universal response of the p38 / 
MAPKs to stress suggests that similar mechanisms could be in-
volved in the control of other somatic stem cell populations.
Materials and methods
Cell culture
MM14 cells were grown on gelatin-coated plates in growth media consist-
ing of Ham’s F10C or F12C media supplemented with 15% horse serum
as previously described (Clegg et al., 1987). FGF-2 was added in in-
creasing concentrations (from 0.3 to 2.5 nM) every 12 h, depending on
cell density. Proliferation media was replaced every 24 h. Differentiation
inducing culture media is comprised of Ham’s F10C or F12C media sup-
plemented with 15% horse serum and no added FGF-2 unless otherwise
noted. Primary myofibers were isolated and cultured as described previ-
ously (Cornelison et al., 2004).
Myofiber preparation, immunohistochemistry, and scoring
Myofibers with their associated satellite cells were prepared as described
previously (Cornelison et al., 2004). In brief, muscle was dissected from
adult mouse hindlimbs and digested with collagenase type I (Worthington)
to yield single intact myofibers. BrdU is routinely added to cultures to facil-
itate cell cycle studies. Additional supplements to the medium included 50
 M SB203580 in DMSO or the DMSO carrier as a control. At the desig-
nated time points after harvest fibers were fixed and stained as described
above. Primary antibodies and dilutions used also included rabbit affinity
purified polyclonal anti-p38 (C-20) (Santa Cruz Biotechnology, Inc.) at
1:50, mouse monoclonal anti–phospho-p38 (New England BioLabs, Inc.)
at 1:50, mouse monoclonal anti-BrdU (BMB) at 1:10, mouse monoclonal
anti-MyoD (Novocastra) at 1:10, and mouse monoclonal anti-myogenin
(F5D; Cusella-DeAngelis et al., 1992), neat, chicken anti–mouse synde-
can-4 (1:1,500). Secondary antibodies anti–rabbit, anti–mouse, and anti–
chicken Alexa 488, anti–rabbit, anti–mouse Alexa 504, and anti–rat Cas-
cade blue were purchased from Molecular Probes, Inc. and were used at
1:500 unless otherwise indicated. Counts of resident satellite cells per myo-
fiber were done by counting DAPI-stained myofiber nuclei (which can be
identified by their characteristic elongated shape) and DAPI-stained satel-
lite cell nuclei coincident with syndecan-4–positive cell outlines. At least
20 myofibers containing at least 5,000 myonuclei total were counted per
time point per condition. Counts of MyoD-positive satellite cells were done
by counting MyoD-positive DAPI-stained nuclei within syndecan-4–positive
cell outlines and comparing to counts of total DAPI-stained nuclei within
syndecan-4–positive cell outlines.
Primary satellite cell cultures
Primary satellite cells were isolated and cultured as described previously
(Cornelison et al., 2004) on gelatin-coupled coverslips, incubated in dif-
ferentiation media for 48 h (with 2.5% horse serum), and 20  M
SB20350 or DMSO fixed and stained with anti–syndecan-4 and MF20
antibodies at 1:1,500 and neat, respectively. Secondary antibodies were
Alexa 488 and Alexa 504 at 1:500. Syndecan-4–positive cells were
scored for MF-20 (MyHC) staining and plotted as a function of the synde-
can-4–positive cells in the population.
Microscopy and image acquisition
All microscope images were obtained on a microscope (model E800; Ni-
kon) using a 60  plan Apo lens at RT using a Cooke Sensicam digital
camera and Intelligent Imaging Innovations Slidebook software to acquire
images on a Macintosh computer. Fluorescence from labeled secondary
antibodies was subtracted from all fluorescent images. Images were ex-
ported into Photoshop, if necessary the brightness and contrast was ad-
justed to the entire image, the image cropped and individual color chan-
nels extracted without color correction adjustments or gamma adjustments.
RT-PCR analysis of MAPK expression
MM14 cells were cultured on 100-mm plates under differentiating condi-
tions (F10C supplemented with 1.5% horse serum) for 0, 6, 12, 24, and
72 h (five plates at a density of 250,000 cells per plate for each treat-
ment). Total RNA was isolated as previously described (Chomczynski and
Sacchi, 1987). 5  g of total RNA was added to reverse transcriptase
buffer (GIBCO BRL) containing 0.025 Oligo (dT)12-18 (GIBCO BRL), 0.01 M
DTT (GIBCO BRL), 0.5 mM dNTP mix (GIBCO BRL), and 200 U of Su-
perscript II reverse transcriptase (GIBCO BRL) and incubated for 50 min at
42 C. Nonreverse transcriptase controls were performed as described
above with the exception of reverse transcriptase addition.
PCR amplification was performed by adding increasing concentra-
tions of cDNA in 2  l (1:100, 1:10 dilution, undiluted) to PCR buffer con-
taining 0.25 mM each dNTP, 1.5 mM MgCl2, 0.5  M each of forward
and reverse primers for ERK1/2, ERK3, ERK5, p38 / , p38 , MyoD,
FGFR-1, 18S RNA, and 5U of Taq polymerase (GIBCO BRL). Each reaction
was amplified for 35 cycles using the following parameters: denaturation
94 C for 1 min, annealing at 50 C for 1 min, and elongation for 1 min. Af-
ter amplification, each reaction was resolved on a 0.8% agarose gel con-
taining ethidium bromide and visualized with a UV transilluminator.
Western analysis
MM14 cells, at a density of 5   10
5 cells per 100-mm plate, were washed
three times with 5 ml of PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4 •7H2O, 1.4 mM KH2PO4, pH 7.3) and then grown in growth
media containing 1.5% horse serum in the absence of added FGF-2 for 0,
6, 12, 24, and 72 h. Alternatively, MM14 cells were grown in differentia-
tion media for 2 h, then DMSO, PD098059 (50  M), U0126 (25  M), or
SB203580 (25  M) was added and the cells grown for an additional 24 h.
Cells were stimulated for 10 min with either 0.1 nM FGF-2 or 100 nM
12-O-tetra-decanoylphorbol-13-acetate as indicated. Cell lysates were pre-
pared as previously described. Protein concentrations were determined by
bicinchonic acid protein assay (Pierce Chemical Co.). Extracted proteins
(20  g) were resolved by SDS-PAGE and electrophoretically transferred to
Immobilon-P (Millipore) in 25 mM ethanolamine, 25 mM glycine, 20%
methanol, pH 9.5. Nonspecific binding sites were blocked with 5% nonfat
dried milk, 0.05% Tween 20 in PBS. p38 /  activity was determined by
probing blots with anti–phospho-p38 /  antibodies (New England Bio-
labs, Inc.), and p38 expression was determined by probing with anti-p38
(C20) antibodies (Santa Cruz Biotechnology, Inc.). Bound antibodies were
detected with either anti–rabbit IgG or anti–mouse IgG conjugated to HRP
(Promega). Bound antibody complexes were visualized by Renaissance
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DNA synthesis assay
DNA synthesis was assayed by [
3H]thymidine incorporation. In brief,
MM14 cells were synchronized by mitotic shake-off and plated in to 24-
well plates at density 2,000 cells/well in the presence or absence of exog-
enous FGF. The cells were grown with the addition of 7.5  l of DMSO or
increasing concentrations of SB203580 for 8 h and then given 2  Ci of
[
3H]thymidine (DuPont) and incubated for an additional 6 h. The amount
of [
3H]thymidine incorporated into DNA was determined by liquid scintil-
lation counting as described previously.
For time course assays, MM14 cells were synchronized by mitotic
shake-off and plated in growth media with 2  Ci of [
3H]thymidine (Du-
pont) in the presence or absence of exogenous FGF-2,and either 25  M
SB203580 or 500 pM FGF-2 was added at increasing time intervals. The
cells were grown for a total of 14 h after plating. The amount of [
3H]thymi-
dine incorporated into DNA was determined by liquid scintillation count-
ing as described previously. Thymidine incorporation for each sample
was normalized to the thymidine incorporation of MM14 cells grown en-
tirely in proliferating conditions.
Additionally, MM14 cells were cultured in differentiation media
and in the presence or absence of 25  M SB203580 for 24 h. Cells were
washed three times with PBS and media replaced with either growth or
differentiation culture media with 2  Ci of [
3H]thymidine (Dupont). The
cells were grown for 12 h and the amount of [
3H]thymidine incorporated
into DNA was determined by liquid scintillation counting. Thymidine incor-
poration for each sample was normalized to the thymidine incorporation
of MM14 cells grown entirely in proliferating conditions.
Analysis of myosin heavy chain expression
MM14 cells were plated onto 6-well plates at a cell density of 8,000
cells/well in growth medium. After 6 h, either 2.5  l of DMSO or
SB203580 (50  M) was added to the wells and cells were grown in the
presence or absence of FGF-2 as described above. At either 36 h or 72 h
after treatment, cells fixed and stained for myosin heavy chain expression
as described previously (Kudla et al., 1995). MHC-positive cells were
scored as a percentage of entire cell population. A minimum of 1,000 to-
tal cells was scored per plate. For time course assays, MM14 cells were
synchronized by mitotic shake-off and plated in differentiation media and
25  M SB203580 was added at increasing time intervals (0, 6, 12, 18,
and 24 h) after plating. Cells were fixed 36 h after plating and stained for
MHC expression. MHC-positive cells were scored as a percentage of en-
tire cell population. A minimum of 1,000 total cells were scored per plate.
Alternatively, MM14 cells were cultured in either proliferation media or
differentiation media in the presence or absence of 25  M SB203580.
36 h after plating, cells were either fixed and stained for MHC expression
or washed three times in PBS (to remove residual SB203580) and media
replenished with either proliferation or differentiation media.
Immunoprecipitation
MM14 cells (3   10
5 per plate, two plates each condition) in proliferation
media were maintained in proliferation media or switched to differentia-
tion media in the presence of either 20  M SB203580 or DMSO. Prolif-
erating cells were harvested 24 h later by centrifugation. Additional
SB203580 or DMSO was added to differentiating cultures at 24 h and
cells were harvested 24 h later by the same method. Cells were resus-
pended in modified RIPA buffer, sonicated and 100  g of protein was
precleared with protein A–Sepharose beads before being incubated with
3  l of Novus Biologicals ab9344 overnight at 4 C, incubated 1 h at 4 C
with 30  l of prewashed protein A–Sepharose beads, washed and boiled
in SDS-PAGE sample buffer for 10 min and 25  l of supernatant from
each sample separated on a 4–20% gradient gel. Proteins were visual-
ized by silver staining.
Transient transfections
Clonal cell proliferation assay. MM14 cells were plated on 100-mm tissue
culture plates at a density of 3,000 cells per plate and transfected as pre-
viously described. Calcium phosphate-DNA precipitates were made as
described previously using 1  g of a reporter construct containing the cy-
tomegalovirus promoter driving the expression of  -galactosidase (CMV-
LacZ) and 20  g of either control DNA (pBSSK ) (Stratagene) caMKK3,
or dnMKK3 as described previously (Fedorov et al., 2002) or with Lipo-
fectamine 2000 as per manufacturer’s instructions transfected with 1  g
of CMV-LacZ, p38 , or p38 mut per well in a 6-well plate, transferred to
100-cm plates 12 h later and plated at clonal density, then fixed 40 h af-
ter plating and scored.
Muscle-specific reporter gene assay.  MM14 cells were transfected
and assayed as previously described (Fedorov et al., 2002) or plated at
30,000 cells/well (on a 6-well) 12 h before transfection using the Lipo-
fectamine 2000 kit. For transfections, 2  g of plasmid (either p38 ,
p38 mut, or pDNA3) and 0.25  g of LacZ and a muscle reporter (lu-
ciferase driven by the  -cardiac actin promoter) were added per well. All
muscle reporter experiments used 20  M SB203580 or an equivalent vol-
ume of DMSO in each well.
P38 /  MAPK reporter assay
p38 MAPK activity was determined using Pathdetect CHOP reporting sys-
tem (Stratagene) (Xu and Cobb, 1997). For this assay, MM14 cells were
plated on 6-well plates at a density of 10
4 cells/well and cotransfected
with 2.5  g pFR-Luc reporter vector, 500 ng pFA-CHOP vector, and 1  g
CMV-LacZ vector per well. The cells were harvested and assayed for lu-
ciferase and  -galactosidase activities as described previously (Fedorov et
al., 1998).
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